正丹股份 reported revenue of ¥1.04B for the period ended 2026-06-30, -27.2% year on year. Net income was ¥0.24B, a 22.8% net margin on a 28.3% gross margin. The largest revenue line is 酸酐及酯类 at 82% of the total. Free cash flow for the period was ¥0.20B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.04B | -27.2% |
| Gross profit | ¥0.29B | — |
| Operating income | ¥0.27B | — |
| Net income | ¥0.24B | -62.4% |
| Gross margin | 28.3% | Net margin 22.8% |
| Revenue Q/Q | +26.0% | — |
| Segment | Revenue | Share |
|---|---|---|
| 酸酐及酯类 | ¥0.86B | 82.4% |
| 高沸点芳烃溶剂 | ¥0.15B | 14.5% |
| 其他主营业务 | ¥0.03B | 2.5% |
| 其他(补充) | ¥0.01B | 0.6% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.75B | 71.7% |
| R&D | ¥0.02B | 2.1% |
| SG&A | ¥0.02B | 1.7% |
| Tax & other | ¥0.03B | 3.3% |
| Item | Amount |
|---|---|
| Total assets | ¥3.30B |
| Total liabilities | ¥0.12B |
| Shareholders' equity | ¥3.18B |
| Equity / assets | 96.4% |
| Operating cash flow | ¥0.21B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥0.20B |
| Cash conversion (OCF / net income) | 63% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
透景生命 ・ 万通智控 ・ 南京聚隆 ・ 正元智慧 ・ 超频三 ・ 星云股份 ・ 杭州园林 ・ 太龙股份 ・ 金陵体育 ・ 雷迪克 ・ 正海生物 ・ 世纪天鸿
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies